Since tumour cells have exceptional metabolic preferences to meet survival and proliferation needs, it may be a viable therapeutic strategy to treat tumours with PHGDH overexpression by targeting specific enzymes, such as PHGDH19. This evidence concerns the gene PHGDH and neoplasm.